Diabetes mellitus type 2 Cost-Effectiveness of Therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
There are numerous cost effective interventions among diabetic patients. | |||
==Cost-effectiveness of Therapy== | ==Cost-effectiveness of Therapy== | ||
| Line 21: | Line 22: | ||
**[[Screening (medicine)|Screening]] for [[diabetic retinopathy]] once a year. | **[[Screening (medicine)|Screening]] for [[diabetic retinopathy]] once a year. | ||
**Prompt [[vitrectomy]] in patients with [[diabetic retinopathy]], compared to delayed [[vitrectomy]]. | **Prompt [[vitrectomy]] in patients with [[diabetic retinopathy]], compared to delayed [[vitrectomy]]. | ||
*Based on another study, intensive [[blood pressure]] control and [[hypertension]] [[treatment]] lessen the cost, compared to moderate [[blood pressure]] control. On the other hand, rigorous glycemic control and serum [[cholesterol]] lowering increase costs even though improve health outcomes.<ref name="pmid12020335">{{cite journal| author=CDC Diabetes Cost-effectiveness Group| title=Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. | journal=JAMA | year= 2002 | volume= 287 | issue= 19 | pages= 2542-51 | pmid=12020335 | doi=10.1001/jama.287.19.2542 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12020335 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 18:10, 17 August 2020
|
Diabetes mellitus type 2 Microchapters |
|
Differentiating Diabetes Mellitus Type 2 from other Diseases |
|
Diagnosis |
|
Treatment |
|
Medical therapy |
|
Diabetes mellitus Main page |
|
Patient Information |
|---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
There are numerous cost effective interventions among diabetic patients.
Cost-effectiveness of Therapy
- Based on 56 studies done on 20 countries, the following interventions are considered as cost saving interventions in diabetes:[1]
- ACE inhibitor (ACEI) therapy, compared to other antihypertensive treatments for maintaining the goal blood pressure.
- ESRD prevention by using ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB), compared to no ESRD prevention.
- Initiation of Irbesartan treatment when there is microalbuminuria, compared to initiation of Irbesartan treatment at macroalbuminuria stage.
- Thorough foot care in order to prevent foot ulcer.
- Control and assessment of diabetic risk factors and appropriate interventions in order to minimize the complications.
- The aforementioned study also determined the following interventions as very cost-effective interventions in diabetes:[1]
- Intensive lifestyle interventions in prediabetes, compared to standard lifestyle intervention.
- General screening for diabetes in 45 to 54 years old African Americans.
- Intensive glycemic control in newly diagnosed type 2 diabetes, based on the UK Prospective Diabetes Study, compared with conventional glycemic control.
- Initiation of statins in order to prevent cardiovascular disease, compared to no treatment.
- Smoking cessation
- Screening for diabetic retinopathy once a year.
- Prompt vitrectomy in patients with diabetic retinopathy, compared to delayed vitrectomy.
- Based on another study, intensive blood pressure control and hypertension treatment lessen the cost, compared to moderate blood pressure control. On the other hand, rigorous glycemic control and serum cholesterol lowering increase costs even though improve health outcomes.[2]
References
- ↑ 1.0 1.1 Li, R.; Zhang, P.; Barker, L. E.; Chowdhury, F. M.; Zhang, X. (2010). "Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review". Diabetes Care. 33 (8): 1872–1894. doi:10.2337/dc10-0843. ISSN 0149-5992.
- ↑ CDC Diabetes Cost-effectiveness Group (2002). "Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes". JAMA. 287 (19): 2542–51. doi:10.1001/jama.287.19.2542. PMID 12020335.